Ultime notizie per Arbutus Biopharma (NASDAQ:ABUS) Azioni

Arbutus Biopharma

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma Corp

<p>BMO Capital  analyst John Gibson   maintains Source Energy Services (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SHLE#TSX">SHLE</a>) with a Market Perform and raises the price target from C$14 to C$16.</p>


News

Price Target

Analyst Ratings

TSX:SHLE

BMO Capital Maintains Market Perform on Source Energy Services, Raises Price Target to C$16

<p>The University of Michigan&#8217;s widely followed consumer survey showed Friday that confidence hit a six-month high in November, driven by an optimistic future outlook <a href="https://www.benzinga.com/topic/inflation">and stable inflation expectations.</a></p>
<h3 class="wp-block-heading">November Consumer Sentiment Report: Key Highlights</h3>
<ul>
<li>The  consumer sentiment index rose from 70.5 in October to 73 points in November, marking a 3.5% monthly surge and surpassing economist estimates – as tracked by TradingEconomics – of 71, preliminary estimates from the University of Michigan showed.</li>
<li>The sub-index for consumer expectations increased from 71.1 to 78.5 points, marking the highest level since July 2021.</li>
<li>The sub-index for current conditions eased from 64.9 to 64.4. </li>
<li>The year-ahead inflation expectations fell from 2.7% to 2.6%, the lowest since December 2020. Long-term inflation expectations inched slightly higher from 3% to 3.1%.</li>
</ul>
<h3 class="wp-block-heading">Economist Takeaways</h3>
<p>The expectations index surged across all dimensions, reaching its highest reading since July 2021. </p>
<p>&#8220;Expectations over personal finances climbed 6% in part due to strengthening income prospects, and short-run business conditions soared 9% in November. Long-run business conditions increased to its most favorable reading in nearly four years,&#8221; said University of Michigan&#8217;s Surveys of Consumers Director <strong>Joanne Hsu</strong>. </p>
<p>Consumer sentiment is now roughly 50% higher than its June 2022 low, but remains below pre-pandemic readings, Hsu said. She added that interviews for the release concluded Monday and do not include reactions to the presidential election. </p>
<h3 class="wp-block-heading">Market Reactions</h3>
<p>Stocks were little moved Friday, with major U.S. equity indices hovering broadly around the flatline during New York morning trading.</p>
<p>Small caps, tracked by the<strong> iShares Russell 2000 ETF</strong> (ARCA: IWM, inched 0.3% higher.</p>
<p>Real estate and utilities were the best performing sectors, up 1.3% and 1.2%, respectively. </p>
<p>Treasury yields continued to fall on Friday, with the 10-year yield down by 5 basis points. As such, long-dated bond ETFs rallied, with the<strong> iShares 20 + Year Treasury bond ETF</strong> (NASAQ: TLT) rallied 1.3%. </p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/large-cap/24/11/41826586/wall-street-closes-at-record-highs-after-reassurance-from-powell-magnificent-7-hit-17-trillion-tre">Wall Street Hits Record Highs After Powell&#8217;s Speech, Lifts Magnificent 7 Stocks To $17 Trillion In Historic Trading</a></strong></li>
</ul>
<p><em>Photo via Shutterstock. </em></p>


Analyst Color

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

Economics

Markets

Tech

ETFs

iShares Trust Barclays 20+ Year Treasury Bond Fund

US Consumer Sentiment Rises More Than Predicted To 6-Month Highs, Inflation Expectations Hit 4-Year Low

<p>Wedbush  analyst Taz Koujalgi   maintains RingCentral (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) with a Neutral and raises the price target from $36 to $41.</p>


Wedbush Maintains Neutral on RingCentral, Raises Price Target to $41

<p>Shares of <strong>Advanced Micro Devices, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) are up 5% this week, trading at $148.83 Friday morning. The stock has gained following <strong>Donald Trump's</strong> victory in the <a href="https://www.benzinga.com/news/large-cap/24/11/41774549/trumps-big-tech-policies-what-gop-victory-means-for-apple-google-microsoft">2024 U.S. presidential election</a>. </p>
<p>Trump's return to the White House and a Republican-controlled Senate signal a shift in U.S. economic policy, potentially raising investor optimism around benefits for the semiconductor industry.</p>
<p><strong>What To Know:</strong> One driver behind AMD's stock uptick is anticipation of Trump's <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy"> tax policies</a>, which include expanded corporate tax cuts. Analysts predict that lower corporate tax rates could boost AMD's profitability, freeing up capital for reinvestment in its advanced semiconductor production and R&amp;D efforts.</p>
<p>Investors see these policies as advantageous for tech manufacturers like AMD, which face rising costs in developing next-generation chips for data centers, artificial intelligence, and consumer electronics.</p>
<p>Additionally, Trump&#8217;s aggressive trade stance, particularly his focus on tariffs to encourage U.S. manufacturing, could bolster domestic production incentives, a benefit for AMD, which relies on both U.S. and global supply chains.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/insights/short-sellers/24/11/41781031/peering-into-advanced-micro-devicess-recent-short-interest">Peering Into Advanced Micro Devices&#8217;s Recent Short Interest</a></strong></p>
<p><strong>What Else:</strong> However, while a protectionist stance may reduce competition from foreign manufacturers, there's concern that high tariffs, especially a proposed 60% levy on Chinese imports, could disrupt AMD's supply chain and lead to higher component costs. </p>
<p>If implemented, these tariffs could impact AMD's pricing flexibility and competitiveness, especially if China retaliates by limiting access to critical raw materials or manufacturing capacity. Still, the prospect of increased U.S. subsidies and lower tax rates under Trump's administration offers short-term optimism for AMD's growth trajectory. </p>
<p>Analysts caution, however, that long-term challenges persist, including potential inflationary pressures and a volatile trade environment that could strain AMD's cost structure and profitability.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41843928/bitcoin-etfs-saw-record-1-38-billion-inflows-on-thursday">Bitcoin ETFs Saw Record $1.38 Billion Inflows On Thursday</a></strong></p>
<h2 class="wp-block-heading">How To Buy AMD Stock</h2>
<p>Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. </p>
<p>For example, in Advanced Micro Devices&#8217; case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.</p>
<p>According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, AMD has a 52-week high of $227.30 and a 52-week low of $113.06.</p>


What's Going On With AMD Stock This Week?

<p>BMO Capital  analyst Juan Sanabria   maintains Retail Opportunity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROIC#NASDAQ">ROIC</a>) with a Market Perform and raises the price target from $17 to $17.5.</p>


ROIC

BMO Capital Maintains Market Perform on Retail Opportunity, Raises Price Target to $17.5

<p><strong>CleanSpark Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) shares are trading higher by 35% to $13.57 this week. Shares of crypto-related stocks are trading higher this week amid strength in <strong>Bitcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), which reached an all-time high during the U.S. presidential election.</p>
<p>Additionally, CleanSpark announced it <a href="https://www.benzinga.com/pressreleases/24/11/n41714046/cleanspark-releases-october-2024-bitcoin-mining-update">mined 655 bitcoins</a> in October, marking a 32% increase compared to the previous month. As of October 31, the company&#8217;s total bitcoin holdings stood at 8,701.</p>
<p><strong>What To Know:</strong> CleanSpark, a bitcoin mining company, benefits directly from Bitcoin&#8217;s performance due to its extensive mining operations, which generate revenue from accumulating and trading the cryptocurrency.</p>
<p>Bitcoin's surge to an all-time high of $75,358 earlier this week has drawn investors to companies with <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41775353/bitcoin-hits-new-all-time-high-as-donald-trump-wins-second-term-what-now">significant crypto exposure</a>, like CleanSpark. With <strong>President-elect Donald Trump</strong> expected to appoint crypto-friendly regulators, the market anticipates favorable policy shifts, potentially lowering operational costs and enhancing profitability for CleanSpark. </p>
<p>Trump&#8217;s pro-crypto administration also aligns well with CleanSpark's recent growth strategy, which includes increasing its energy-efficient mining capacity to capitalize on rising Bitcoin demand.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41843182/fed-cuts-rates-but-inflation-remains-elephant-in-the-room">Fed Cuts Interest Rates, But Inflation Remains Elephant In The Room</a></strong></p>
<h2 class="wp-block-heading">How To Buy CLSK Stock</h2>
<p>Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. </p>
<p>For example, in Cleanspark&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.</p>
<p>According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, CLSK has a 52-week high of $24.72 and a 52-week low of $3.46.</p>


$BTC

CLSK

Why Bitcoin-Related Stock CleanSpark Is Up 35% This Week

<p>Wedbush  analyst Daniel Ives   reiterates Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) with a Outperform and maintains $20 price target.</p>


Reiteration

RIVN

Wedbush Reiterates Outperform on Rivian Automotive, Maintains $20 Price Target

Trading Ideas

SBET

SharpLink Gaming Shares Halted On Circuit Breaker To The Downside, Stock Now Up 36%

<p>BMO Capital  analyst Jeremy Mccrea   maintains Parex Resources (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PXT#TSX">PXT</a>) with a Market Perform and raises the price target from C$13 to C$14.</p>


TSX:PXT

BMO Capital Maintains Market Perform on Parex Resources, Raises Price Target to C$14

<p>BMO Capital  analyst Jeremy Mccrea   maintains Kiwetinohk Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/KEC#TSX">KEC</a>) with a Outperform and raises the price target from C$18 to C$20.</p>


TSX:KEC

BMO Capital Maintains Outperform on Kiwetinohk Energy, Raises Price Target to C$20

<p>Wedbush  analyst Scott Devitt   maintains Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Neutral and raises the price target from $130 to $180.</p>


EXPE

Wedbush Maintains Neutral on Expedia Group, Raises Price Target to $180

<p><a href="https://x.com/WolfpackReports/status/1854908881161339033" title="https://x.com/WolfpackReports/status/1854908881161339033">https://x.com/WolfpackReports/status/1854908881161339033</a></p>


Short Sellers

INOD

Wolfpack Research Posts On X "$INOD Regulatory Update per the latest Q: 1. Letter received from the SEC in March requesting $INOD preserve certain documents; 2. DOJ grand jury subpoena received in August; 3. SEC subpoena received in September"

<p>BMO Capital  analyst Tom MacKinnon   maintains Intact Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/IFC#TSX">IFC</a>) with a Outperform and raises the price target from C$275 to C$290.</p>


TSX:IFC

BMO Capital Maintains Outperform on Intact Financial, Raises Price Target to C$290

<p><strong>Icahn Enterprises L.P.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IEP#NASDAQ">IEP</a>) shares <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">are trading lower on Friday.</a></p>
<p>The company reported third-quarter earnings per unit of 5 cents, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41839874/icahn-enterprises-l-p-nasdaq-iep-today-announced-its-third-quarter-2024-financial-results" rel="noreferrer noopener">missing the street view of 21 cents</a>. Quarterly sales of $2.22 billion missed the analyst consensus estimate of $2.32 billion.</p>
<p>As of&nbsp;October 31, the firm had approximately&nbsp;$2.3 billion&nbsp;between cash and equivalents at the holding company and the investment funds.&nbsp;</p>
<p>In the third quarter, net income attributable to IEP was $22 million, which is an improvement of $28 million compared to the same quarter last year. Adjusted EBITDA for the third quarter was $183 million, down from $243 million in the prior year&#8217;s quarter.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41845483/taiwan-semiconductor-us-expansion-plans-unfazed-by-trump-win-report" rel="noreferrer noopener">Taiwan Semiconductor US Expansion Plans Unfazed by Trump Win: Report</a></strong></p>
<p>IEP has proposed that its subsidiary, IEH, initiate a tender offer to buy up to 15 million additional shares of <strong>CVR Energy Inc. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVI#NYSE">CVI</a>) common stock at $17.50 per share.</p>
<p>This offer price represents a 6% premium over CVR Energy&#8217;s closing price on November 7, 2024, and a 5% premium over the average price of CVR Energy stock over the last 7 trading days.</p>
<p>IEP said CVR Energy&#8217;s shares are undervalued and sees this as a good investment opportunity. IEP currently beneficially owns, directly and indirectly, 66.3% of the outstanding shares of CVR Energy&#8217;s common stock. If the proposed tender offer were to be fully or over-subscribed, IEP would beneficially own 81.3% of CVR Energy&#8217;s common stock.</p>
<p>As of September 30, Icahn Enterprises&#8217; indicative net asset value decreased by $423 million compared to June 30. This drop was mainly due to a $249 million decline in CVR, a $193 million decrease in Automotive Services, and a $113 million distribution to unitholders, despite a $192 million gain in the investment funds.</p>
<p><strong>Reduces Distribution:</strong> On&nbsp;November 6, the Board of Directors of the general partner of Icahn Enterprises declared a quarterly distribution in the amount of&nbsp;$0.50&nbsp;per depositary unit, which will be paid on or about&nbsp;December 26. The company&nbsp;decreased the quarterly distribution from&nbsp;$1.00&nbsp;per depositary unit.&nbsp;</p>
<p><strong>Price Action:</strong> IEP shares are trading lower by 7.10% to $11.98 at last check Friday.</p>
<p><em>Image from Shutterstock</em></p>
<p><strong>Also Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/24/11/41819699/roblox-tightens-safety-bans-preteens-from-virtual-social-spaces" target="_blank" rel="noreferrer noopener">Roblox Tightens Safety, Bans Preteens from Virtual Social Spaces</a></strong></li>
</ul>


Earnings

Equities

Guidance

Movers

General

Icahn Enterprises Hits Rough Patch With Q3 Earnings Miss, Dividend Cut; Eyes Larger Stake In CVR Energy

WIIM

MRVI

Maravai LifeSciences shares are trading lower after the company reported worse-than-expected Q3 financial results and cut its FY24 sales guidance. Additionally, William Blair downgraded the stock from Outperform to Market Perform and Baird cut its price target from $10 to $9.

<p>Wedbush  analyst Seth Basham   maintains Arhaus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) with a Neutral and lowers the price target from $11 to $10.</p>


ARHS

Wedbush Maintains Neutral on Arhaus, Lowers Price Target to $10

<p>Financial giants have made a conspicuous bullish move on BP. Our analysis of options history for BP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) revealed 12 unusual trades.</p>
<p>Delving into the details, we found 41% of traders were bullish, while 41% showed bearish tendencies. Out of all the trades we spotted, 8 were puts, with a value of $662,350, and 4 were calls, valued at $348,840.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $25.0 to $45.0 for BP over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in BP's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to BP's substantial trades, within a strike price spectrum from $25.0 to $45.0 over the preceding 30 days.</p>
<h3>BP 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731079868_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$12.9</td>
<td>$12.85</td>
<td>$12.9</td>
<td>$42.00</td>
<td>$223.1K</td>
<td>1.2K</td>
<td>173</td>
</tr>
<tr>
<td>BP</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$11.4</td>
<td>$11.35</td>
<td>$11.4</td>
<td>$40.00</td>
<td>$176.7K</td>
<td>1.2K</td>
<td>155</td>
</tr>
<tr>
<td>BP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$6.0</td>
<td>$5.65</td>
<td>$5.65</td>
<td>$25.00</td>
<td>$161.5K</td>
<td>961</td>
<td>286</td>
</tr>
<tr>
<td>BP</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$4.3</td>
<td>$4.2</td>
<td>$4.25</td>
<td>$25.00</td>
<td>$106.2K</td>
<td>3.8K</td>
<td>511</td>
</tr>
<tr>
<td>BP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.39</td>
<td>$1.38</td>
<td>$1.39</td>
<td>$30.00</td>
<td>$66.0K</td>
<td>6.5K</td>
<td>1.1K</td>
</tr>
</tbody>
</table>
</p>
<h3>About BP</h3>
<p>BP is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2023, it produced 1.1 million barrels of liquids and 6.9 billion cubic feet of natural gas per day. At the end of 2023, reserves stood at 6.8 billion barrels of oil equivalent, 55% of which are liquids. The company operates refineries with a capacity of 1.6 million barrels of oil per day.</p>
<p>Having examined the options trading patterns of BP, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>BP's Current Market Status</h3>
<ul>
<li>Trading volume stands at 2,282,868, with BP's price down by -2.52%, positioned at $29.06.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 88 days.</li>
</ul>
<h3>Expert Opinions on BP</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $34.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on BP, which currently sits at a price target of $33.<br />
&#x2A; Reflecting concerns, an analyst from Scotiabank lowers its rating to Sector Perform with a new price target of $36.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for BP with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

BP Options Trading: A Deep Dive into Market Sentiment

<p>BMO Capital  analyst Etzer Darout   reiterates Genmab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMAB#NASDAQ">GMAB</a>) with a Outperform and raises the price target from $46 to $48.</p>


GMAB

BMO Capital Reiterates Outperform on Genmab, Raises Price Target to $48

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Cava Group</strong>.</p>
<p>Looking at options history for Cava Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) we detected 9 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish expectations and 33% with bearish.</p>
<p>From the overall spotted trades, 3 are puts, for a total amount of $106,564 and 6, calls, for a total amount of $202,113.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $85.0 and $140.0 for Cava Group, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Cava Group's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Cava Group's significant trades, within a strike price range of $85.0 to $140.0, over the past month.</p>
<h3>Cava Group 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731079862_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$46.0</td>
<td>$44.8</td>
<td>$46.0</td>
<td>$100.00</td>
<td>$46.0K</td>
<td>3.2K</td>
<td align="right">11</td>
</tr>
<tr>
<td>CAVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$8.2</td>
<td>$7.4</td>
<td>$8.2</td>
<td>$135.00</td>
<td>$41.0K</td>
<td>440</td>
<td align="right">60</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$16.7</td>
<td>$16.5</td>
<td>$16.68</td>
<td>$140.00</td>
<td>$36.7K</td>
<td>1.0K</td>
<td align="right">39</td>
</tr>
<tr>
<td>CAVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$12.2</td>
<td>$11.7</td>
<td>$11.9</td>
<td>$140.00</td>
<td>$35.5K</td>
<td>270</td>
<td align="right">31</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$14.9</td>
<td>$13.1</td>
<td>$13.1</td>
<td>$135.00</td>
<td>$34.0K</td>
<td>629</td>
<td align="right">26</td>
</tr>
</tbody>
</table>
</p>
<h3>About Cava Group</h3>
<p>Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates the majority of its revenue from the CAVA segment.</p>
<p>In light of the recent options history for Cava Group, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Cava Group</h3>
<ul>
<li>Currently trading with a volume of 1,240,181, the CAVA's price is up by 0.75%, now at $140.04. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 4 days.</li>
</ul>
<h3>What Analysts Are Saying About Cava Group</h3>
<p>3 market experts have recently issued ratings for this stock, with a consensus target price of $133.66666666666666.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Neutral rating for Cava Group, targeting a price of $140.<br />
&#x2A; An analyst from Barclays persists with their Equal-Weight rating on Cava Group, maintaining a target price of $113.<br />
&#x2A; An analyst from Baird persists with their Outperform rating on Cava Group, maintaining a target price of $148. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Cava Group with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


CAVA

Cava Group's Options Frenzy: What You Need to Know

<p>High-rolling investors have positioned themselves bullish on Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in FCX often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 10 options trades for Freeport-McMoRan. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 50% bullish and 50% bearish. Among all the options we identified, there was one put, amounting to $49,775, and 9 calls, totaling $722,085.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $44.0 to $50.0 for Freeport-McMoRan during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Freeport-McMoRan's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Freeport-McMoRan's significant trades, within a strike price range of $44.0 to $50.0, over the past month.</p>
<h3>Freeport-McMoRan Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731079857_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$2.8</td>
<td>$2.68</td>
<td>$2.75</td>
<td>$50.00</td>
<td>$138.0K</td>
<td>2.8K</td>
<td align="right">521</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$4.45</td>
<td>$4.35</td>
<td>$4.45</td>
<td>$45.00</td>
<td>$129.0K</td>
<td>1.4K</td>
<td align="right">294</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$4.65</td>
<td>$4.55</td>
<td>$4.6</td>
<td>$48.00</td>
<td>$120.9K</td>
<td>231</td>
<td align="right">343</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$3.6</td>
<td>$3.55</td>
<td>$3.6</td>
<td>$44.00</td>
<td>$105.1K</td>
<td>648</td>
<td align="right">307</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$4.65</td>
<td>$4.6</td>
<td>$4.6</td>
<td>$48.00</td>
<td>$78.0K</td>
<td>231</td>
<td align="right">527</td>
</tr>
</tbody>
</table>
</p>
<h3>About Freeport-McMoRan</h3>
<p>Freeport-McMoRan Inc is an international mining company. It has organized its mining operations into four primary divisions: North America copper mines, South America mining, Indonesia mining and Molybdenum mines. Its reportable segments include the Morenci, Cerro Verde and Grasberg (Indonesia mining) copper mines, the Rod &amp; Refining operations and Atlantic Copper Smelting and Refining. It derives key revenue from the sale of Copper.</p>
<p>Following our analysis of the options activities associated with Freeport-McMoRan, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is Freeport-McMoRan Standing Right Now?</h3>
<ul>
<li>With a volume of 2,903,867, the price of FCX is down -4.6% at $46.35. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 75 days.</li>
</ul>
<h3>Professional Analyst Ratings for Freeport-McMoRan</h3>
<p>3 market experts have recently issued ratings for this stock, with a consensus target price of $54.666666666666664.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for Freeport-McMoRan, targeting a price of $55.<br />
&#x2A; An analyst from Raymond James has decided to maintain their Outperform rating on Freeport-McMoRan, which currently sits at a price target of $57.<br />
&#x2A; Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Perform rating for Freeport-McMoRan, targeting a price of $52. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Freeport-McMoRan, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Unpacking the Latest Options Trading Trends in Freeport-McMoRan

Arbutus Biopharma (ABUS) has released an update. Arbutus Biopharma is set to showcase promising clinical data on its RNAi therapeutic, imdusiran, a...

Arbutus Biopharma Highlights Imdusiran's Potential in Hepatitis B

Tourlite Capital Q3 2024 Investor Letter

Arbutus Biopharma (ABUS) has released an update. Arbutus Biopharma is set to release its third quarter 2024 financial results and provide a corpora...

Arbutus Biopharma to Announce Q3 2024 Results

Arbutus Biopharma Q3 2024 Earnings Preview

Here's the major earnings before the open tomorrow

Arbutus Biopharma (ABUS) has released an update. Arbutus Biopharma reported promising results from its Phase 2a trials for imdusiran, a potential t...

Arbutus Biopharma Reports Promising Clinical Trial Results

JMP Securities analyst Roy Buchanan reiterated a Buy rating on Arbutus Biopharma (ABUS – Research Report) today and set a price target of $5.00. Ro...

Arbutus Biopharma's Promising Clinical Developments and Strong Financial Position Justify Buy Rating

Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript

Keay Nakae, an analyst from Chardan Capital, maintained the Buy rating on Arbutus Biopharma (ABUS – Research Report). The associated price target i...

Promising Developments in Arbutus Biopharma's Pipeline Lead to Buy Rating and Increased Price Target

Chardan raised the firm's price target on Arbutus Biopharma (ABUS) to $4.50 from $4 and keeps a Buy rating on the shares after its Q3 results. The ...

Arbutus Biopharma price target raised to $4.50 from $4 at Chardan

ABUS

ADRNY

ATHM

AUDC

BMWYY

CELH

CLBT

CNDT

EHTH

ENOV

FOLD

FTAI

FTAIM

FTAIN

FTAIO

FTAIP

HENKY

IONS

LNTH

MCFT

MKTX

MOGO

NEON

OESX

PERI

PFGC

PRGO

ROIV

RPRX

SNDR

STWD

TCPC

TEVA

TRMB

URGN

VONOY

VRNOF

Health Care

Press Releases

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Biotech

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Arbutus to Participate in Two Upcoming Investor Conferences

Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Comments

Arbutus Biopharma

Notizie

Ultime notizie per Arbutus Biopharma (NASDAQ:ABUS) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO